Dec 9 (Reuters) - Anti-wrinkle injection maker Revance
Therapeutics ( RVNC ) has agreed to be bought for $3.10 per
share by privately held Crown Laboratories, instead of $6.66 per
share agreed previously, the two companies said on Monday.
Shares of Revance were down 20.4% in premarket trade.